STAT

With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition

With new clinical trial results, Intercept Pharma will seek approval for first-ever treatment for NASH, a fatty liver condition.

Intercept Pharmaceuticals (ICPT) said Tuesday that an experimental medicine to treat the fatty liver disease known as NASH achieved its primary goal in a Phase 3 clinical trial, giving it a shot at becoming the first drug to treat the condition and turning it into a potential blockbuster commercial opportunity.

Based on the data collected

You're reading a preview, sign up to read more.

More from STAT

STAT10 min readPolitics
How Joe Grogan, A Former Pharma Lobbyist, Upended Trump’s Drug Pricing Agenda
This brash, combative former pharma lobbyist is one of the most powerful Trump aides you’ve never heard of. He’s reshaping the administration’s drug pricing policy by blocking one idea at…
STAT4 min read
Opinion: International Pricing Index ‘Accomplishes Nothing It Sets Out To Do’
Let's find a better solution than the international pricing index, which is like 1970s-style rent control: both artificially lower pricing and ultimately limit supply.
STAT5 min read
Opinion: Motherhood And Medicine Should Mix. So Why Is It Such A Struggle?
I've learned to deal with the overt discrimination that comes with being a visual minority in medicine. Resistance against my being a mother, on the other hand, seemed to be…